$45.97
Live
1.0%
Downside
Day's Volatility :3.23%
Upside
2.25%
70.15%
Downside
52 Weeks Volatility :71.61%
Upside
4.87%
Period | Protagonist Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 30.11% | 3.6% | 0.0% |
6 Months | 76.51% | 10.2% | 0.0% |
1 Year | 234.31% | 19.6% | 0.0% |
3 Years | 51.27% | 16.8% | -23.0% |
Market Capitalization | 2.8B |
Book Value | $9.21 |
Earnings Per Share (EPS) | 2.72 |
PE Ratio | 17.29 |
PEG Ratio | 0.0 |
Wall Street Target Price | 52.71 |
Profit Margin | 53.26% |
Operating Margin TTM | -930.96% |
Return On Assets TTM | 20.35% |
Return On Equity TTM | 40.69% |
Revenue TTM | 319.1M |
Revenue Per Share TTM | 5.28 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 26.6M |
EBITDA | 153.2M |
Diluted Eps TTM | 2.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 1.96 |
EPS Estimate Next Year | -1.36 |
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Next Quarter | -0.69 |
What analysts predicted
Upside of 14.66%
Sell
Neutral
Buy
Protagonist Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Protagonist Therapeutics Inc | 1.78% | 76.51% | 234.31% | 51.27% | 291.09% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Protagonist Therapeutics Inc | 17.29 | 17.29 | 0.0 | 1.96 | 0.41 | 0.2 | NA | 9.21 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Protagonist Therapeutics Inc | Buy | $2.8B | 291.09% | 17.29 | 53.26% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Farallon Capital Management, L.L.C.
BlackRock Inc
RTW INVESTMENTS, LLC
Bvf Inc
Vanguard Group Inc
Johnson & Johnson
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Organization | Protagonist Therapeutics Inc |
Employees | 125 |
CEO | Dr. Dinesh V. Patel Ph.D. |
Industry | Health Technology |
International Select Dividend Ishares
$45.97
-2.13%
Vanguard Ultra Short Bond Et
$45.97
-2.13%
Core Scientific Inc
$45.97
-2.13%
Integer Holdings Corp
$45.97
-2.13%
Liberty Global Plc - Class C Shares
$45.97
-2.13%
Pampa Energia Sa
$45.97
-2.13%
Icf International Inc
$45.97
-2.13%
Pacific Premier Bancorp Inc
$45.97
-2.13%
Macy's, Inc.
$45.97
-2.13%